Bevacizumab: Oncolytic

摘要

The role of angiogenesis in the growth and metastasis of tumors is well established. Research has therefore focused on developing agents that target angiogenic factors such as vascular endothelial growth factor (VEGF) in order to inhibit tumor growth. One such agent is bevacizumab, a humanized monoclonal antibody generated by engineering the VEGF binding residues of a murine neutralizing antibody into the framework of a normal human immunoglobulin G (IgG). Bevacizumab recognizes VEGF receptors 1 and 2 (VEGFR-1 and VEGFR-2) and thus can neutralize the biologically active forms of VEGF that interact with these receptors. Bevacizumab has shown antiangiogenic and preclinical antitumor activity and was chosen for further development as a treatment for breast cancer and colorectal cancer.